Ongoing ACR advocacy efforts are working to keep biologic drugs accessible to rheumatology patients, defending the ability of rheumatology practices to use the complex chemotherapy codes for administration of biologic therapies.
The ACR Responds to Impact of the Dobbs v. Jackson Decision on Rheumatology Patients and Providers
The ACR and a new Access to Reproductive Health Care Task Force are working to ensure patients with rheumatic disease—particularly women—have access to the medications and treatments they need, including methotrexate, and that rheumatology providers are able to maintain trusting relationships with and advise their patients on all matters relevant to the management of their rheumatic diseases.
Cigna Delays Modifier 25 Policy Change for Evaluation & Management Services
Cigna will not move forward with changes to their reimbursement policy for evaluation and management (E/M) codes submitted with modifier 25 as originally scheduled.
Providers Who Received Period 1 Relief Funds May Request to Submit Late Reports
Practices that received Provider Relief Funds between April 10–June 30, 2020, and did not file a report may request to submit a late report and avoid having funds recouped.
The Power of Advocacy
In 1916, a handful of conservation advocates successfully lobbied Congress to create the National Park Service, which now protects more than 85 million acres of U.S. land. Dedicated rheumatology advocacy has lasting effects, too, as evidenced by several policy wins in 2021 and efforts underway for 2022.
CVS Caremark to Revise Prior Authorization Forms in January 2022
The reassurance comes after ACR leadership sent a letter detailing how its prior authorization forms increased paperwork burden for many biologic drugs and hurt patients’ timely access to treatment.
Congress Acts to Avert Nearly 10% Cut to Medicare Reimbursement Set for 2022
Updated Dec. 16, 2021: In response to advocacy from the ACR and other provider and patient groups, Congress passed legislation to avoid the nearly 10% “Medicare cliff” scheduled to take effect Jan 1. The ACR thanks all ACR/ARP members and patients who took the time to engage in this critical effort with us to protect…
ACR Works for Modifications to Build Back Better Act
The ACR has long supported efforts to reduce drug prices through many of the provisions included in the House-passed version of the Build Back Better Act. However, the current wording of one provision puts patient access to Medicare Part B treatments at risk.
The ACR Thanks 2021 RheumPAC Matching Campaign Donors
With a record-high 46 first-time contributors, this year’s matching campaign raised more than $26,000 from members and another $17,000 from volunteer leaders who made a pledge for each donor, advancing advocacy efforts on behalf of rheumatology.
ACR Considers Healthcare Policies in Build Back Better Act
The ACR will be working with the Senate as they consider and debate the important healthcare policies contained in this massive legislation.
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- 9
- Next Page »